Pharma R&D productivity continues to decline despite a host of tech advances: "The average cost for [pharma] companies to bring a drug to market has increased to record levels of just under $2 billion, up from $1,188 million in 2010 and $1,539 million in 2016."
-
-
The goal is to make drugs that will be effective *in live humans*. If you don’t have a way of speeding up the feedback loop, or if you don’t have some fundamental advance in biology/knowledge, then how are you going to be 10x better than big pharma at this?
Show this thread -
Moreover — getting results with AI requires both fast feedback loops (gaming!) and proprietary data. How (if at all) are these startups getting/generating data that is proprietary and that gives them some kind of competitive advantage?
Show this thread -
I’m curious to hear from people who are more bullish on this than I am. Until we fix the above problems, it seems to me that drug discovery will not accelerate in the way that more internet-ish fields are, and I would be bearish on the average biotech startup.
Show this thread -
I also glossed over explaining the 2 fundamental problems above properly, because this is Twitter, but would be happy to write an essay on this if there’s interest
Show this thread -
It wouldn’t surprise me if R&D productivity were still in stagnation in 20 years. One implication of this for people who want quicker results (which is most tech people) is that “prevention” is a more promising vector for health than “curing”.
Show this thread
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.
→
.